Hoyt J A, Fisher L F, Swisher D K
Toxicology Research Laboratories, Eli Lilly and Company, Greenfield, IN 46140, USA.
Reprod Toxicol. 1995 May-Jun;9(3):315-26. doi: 10.1016/0890-6238(95)00014-2.
Sulfasalazine (2-hydroxy-5-[[4-[(2-pyridinylamino) sulfonyl] phenyl]azo]benzoic acid; SASP) was administered to rats in a short-term male reproductive toxicity study to further examine the utility of this grouping of techniques and to generate reference data with a substance that is known to cause reversible infertility in men. Adult male CD rats (10/group) were orally administered 0, 150, 300, or 600 mg SASP/kg body weight in divided doses for 14 d followed by a 2-week period without treatment. Males were killed on test day (TD) 15 or 29. At each time point, the reproductive system was evaluated by comparing testicular and epididymal weights, DNA ploidy distributions of testicular cell suspensions, testicular and epididymal histopathology, and epididymal sperm concentrations, motion, morphology, and breakage. Adding time as a factor in the protocol aids in distinguishing testicular from posttesticular effects. Changes in sperm quality after 2 weeks of test article administration (TD 15) predominantly reflect effects that occurred after the sperm entered the epididymis, while testicular effects predominated on TD 29. Beginning on TD 14, males to be killed on TD 29 were cohabited with untreated females (1:2). Females were killed at midgestation and examined for pregnancy status. Body weight gain was depressed in all SASP groups during the first 3 d of test article administration. Food consumption was depressed at the 300- and 600-mg/kg dose levels. No changes were seen in testicular weight, but epididymal weight was depressed at the 600-mg/kg dose level. DNA ploidy distributions determined by flow cytometry did not indicate that the kinetics of spermatogenesis were disturbed. However, alterations in sperm release, which have not previously been reported, were seen at all SASP dose levels. On TD 29, the percentage of progressively motile sperm was depressed and beat/cross frequency was increased at the 600-mg/kg dose level. No changes were observed in sperm morphology or breakage. Fertility was slightly depressed at the 600-mg/kg dose level. In this study, testicular histopathology provided the most sensitive endpoint for reproductive toxicity. The impairment of fertility immediately after treatment was stopped, when no changes were apparent in sperm release or sperm motion, suggested that decreased sperm concentrations and altered motility, while contributory, may not be the primary causes of SASP-mediated infertility.
柳氮磺胺吡啶(2-羟基-5-[[4-[(2-吡啶基氨基)磺酰基]苯基]偶氮]苯甲酸;SASP)被用于一项短期雄性生殖毒性研究,以进一步检验该技术组合的实用性,并使用一种已知会导致男性可逆性不育的物质生成参考数据。成年雄性CD大鼠(每组10只)按体重分剂量口服给予0、150、300或600mg SASP/kg,持续14天,随后有2周未进行处理的时期。在试验日(TD)15或29处死雄性大鼠。在每个时间点,通过比较睾丸和附睾重量、睾丸细胞悬液的DNA倍性分布、睾丸和附睾组织病理学以及附睾精子浓度、活力、形态和破损情况来评估生殖系统。在实验方案中加入时间因素有助于区分睾丸效应和睾丸后效应。给药2周后(TD 15)精子质量的变化主要反映精子进入附睾后发生的效应,而在TD 29时睾丸效应占主导。从TD 14开始,将在TD 29处死的雄性大鼠与未处理的雌性大鼠(1:2)合笼。在妊娠中期处死雌性大鼠并检查妊娠状态。在给药的前3天,所有SASP组的体重增加均受到抑制。在300和600mg/kg剂量水平时食物消耗受到抑制。睾丸重量未见变化,但在600mg/kg剂量水平时附睾重量受到抑制。通过流式细胞术测定的DNA倍性分布未表明精子发生动力学受到干扰。然而,在所有SASP剂量水平均观察到了此前未报道的精子释放改变。在TD 29时,在600mg/kg剂量水平时,进行性运动精子的百分比降低,拍打/交叉频率增加。精子形态或破损未见变化。在600mg/kg剂量水平时生育力略有降低。在本研究中,睾丸组织病理学为生殖毒性提供了最敏感的终点。在停止治疗后立即出现生育力受损,而此时精子释放或精子活力无明显变化,这表明精子浓度降低和活力改变虽然有影响,但可能不是SASP介导的不育的主要原因。